Navigation Links
Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
Date:3/29/2011

SAN DIEGO, March 29, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) presentation taking place at the American College of Cardiology (ACC) 60th Scientific Session, April 2-5.

ACC:  Ernest N. Morial Convention Center (Expo Hall), New Orleans, LA.  Sunday, April 3:  Poster PresentationAbstract: 286Presenter: Jorge Plutzky, MD, Director, Vascular Disease Prevention Program, Brigham and Women's Hospital, Boston, MATitle: "Weight Loss, Blood Pressure, Pulse and Circadian Patterns with Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy for Obesity"Time: 10:00 – 11:15 a.m. CDTLocation: Hall FSession Title: Risk Reduction and Rehabilitation:  Role of Exercise IIAbout Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product, Contrave®, has completed Phase 3 clinical trials and has received a Complete Response letter from the FDA for its New Drug Application.  The company is in the process of determining the next steps for Contrave.  The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.


'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen® Therapeutics Announces Corporate Realignment
2. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
3. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
4. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
5. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
6. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
7. Northwest Biotherapeutics Addresses Recent Market Activity
8. MBL Signs Non-Exclusive License With Envoy Therapeutics for Access to RIP-Chip Technology
9. FDA Provides Guidance for Design of Cell Therapeutics Pixantrone Pivotal Trial
10. Reportlinker Adds Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
11. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... and implementation of CLEARAS Water Recovery’s Advanced Biological Nutrient Recovery (ABNR™) technology at ... of a $24 million plant upgrade to sustainably meet current and future nutrient ...
(Date:5/23/2017)... Canada (PRWEB) , ... May 23, 2017 , ... ... Firmex FileSend, a cloud-based file transfer solution that makes it easy for organizations ... without having to worry about cumbersome FTP software or email file size limitations. ...
(Date:5/23/2017)... Washington, USA (PRWEB) , ... May 22, 2017 ... ... SPIE Optics and Photonics 2017 in San Diego, California, this August will ... reality, solar fuels, and autonomous vehicles. , SPIE Optics and Photonics, the largest ...
(Date:5/23/2017)... Massachusetts (PRWEB) , ... May 23, 2017 , ... ... making a splash at this year’s Bio-IT World Conference and Expo in ... Smart Data Lake® 4.0 solution. The Anzo Smart Data Lake is also a ...
Breaking Biology Technology:
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
Breaking Biology News(10 mins):